Brief: SAB Biotherapeutics Announces Progress On U.S. FDA's Phased Review Of Company's Groundbreaking DiversitAb Platform
09/05/2023 14:10
May 9 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS ANNOUNCES PROGRESS ON U.S. FDA’S
PHASED
REVIEW OF COMPANY’S GROUNDBREAKING DIVERSITAB™ PLATFORM
* SAB BIOTHERAPEUTICS INC- FDA APPROVED 5 OF 7 SECTIONS IN
ROLLING
SUBMISSION FOR A NADA FOR CO'S ANTIBODY GENERATING DIVERSITAB
PLATFORM IN TC BOVINE
Source text for Eikon: ID:nGNX59ysCv
Further company coverage: SABS.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies